2141-V11 在对标准治疗无反应的非肌肉浸润性膀胱癌患者中的研究
I 期研究评估膀胱内抗 CD40 激动剂抗体 (2141-V11) 在对卡介苗治疗无反应的非肌肉浸润性膀胱癌患者中的安全性和耐受性
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see which dose is safest in people. The researchers will also do tests to see how the body absorbs, distributes, and gets rid of 2141-V11. This study is one of the first to test 2141-V11 in people, and the first to test 2141-V11 delivered through a catheter into the bladder.
研究概览
地位
条件
详细说明
If during Period 1 treatment, the treating physician notices recurrent disease in the bladder, the patient should undergo a biopsy or TURBT. If the pathology returns as HG Ta or CIS, the patient can resume treatment. If pathology returns as HG T1, the patient will be removed from treatment. If a high-grade recurrence occurs during period 2 or 3 treatments, the patient will be removed from treatment.
Cohort B is organized into two parts. Cohort B Part 1 is the completed safety assessment of fixed-dose intratumoral 2141-V11 (10 mg) monotherapy. Cohort B Part 2 is a randomized, open-label, pilot Phase II expansion employing a selection design to evaluate the clinical efficacy of intratumoral 2141-V11 (10 mg) in combination with intravesical gemcitabine (2000 mg in 100 mL) compared to intravesical gemcitabine monotherapy (2000mg in 100 mL) in subjects with BCG-naïve high-grade Ta NMIBC. Subjects will be randomized 1:1 to the combination arm or the gemcitabine monotherapy arm.
***Continuation of Inclusion/Exclusion Criteria
Known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include:
-
Basal cell carcinoma of the skin
-
Squamous cell carcinoma of the skin that has undergone potentially curative therapy
-
In situ cervical cancer
-
History of prostate cancer treated with definitive intent (surgical or radiation therapy), provided that the following criteria are met: stage T2N0M0 or lower with a Gleason score ≤7 and prostate-specific antigen (PSA) undetectable for at least 1 year while off androgen deprivation therapy, that was either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study enrollment
-
Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
-
Ongoing immune related adverse event ≥ grade 2, or who require > 10 mg/day prednisone (or equivalent) to treat immune related adverse event. Note: patients who are on stable doses of physiologic corticosteroid replacement only (i.e.,hydrocortisone < 50 mg in a 24-hour period, or equivalent) are eligible.
- Diagnosis of immunodeficiency, concurrent immune suppressive disease, or is receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 4 weeks prior to the planned first dose of trial treatment. The use of physiologic doses of corticosteroids as replacement therapy (for adrenal or pituitary insufficiency, etc.) is acceptable. Topical and inhaled corticosteroids in standard doses are acceptable.
- Known contraindications to intravesical therapy:
-
Febrile illness, symptomatic urinary tract infection, or persistent gross hematuria
-
Traumatic catheterization or gross hematuria on day of treatment
- Active infection requiring systemic therapy, including active or intractable urinary tract infection within 4 weeks prior to the first dose of trial treatment
- Severe infection within 4 weeks prior to the first dose of trial treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis
- History of Human Immunodeficiency Virus (HIV) infection (e.g., positive HIV-1/2 antibodies)
- Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C [e.g., HCV RNA (qualitative) detected] infection; subjects with past/resolved Hepatitis B Virus (HBV) infection (defined as having a negative HBsAg and a positive antibody to Hepatitis B coreantigen) or Hepatitis C Virus (HCV) infection are eligible only if polymerase chain reaction (PCR) testing is negative for HBV DNA or HCV RNA, respectively (must be obtained within 28 days prior to treatment initiation) Pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment
- History of pulmonary embolism or any other thromboembolic event within 6 months prior to enrollment
- History of undergoing an allogeneic tissue/solid organ transplant
- History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the trial, interfere with the subject's ability to cooperate with the requirements of the trial, confound the results of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Eugene Pietzak, MD
- 电话号码:646-422-4781
研究联系人备份
- 姓名:Bernard Bochner, MD
- 电话号码:646-422-4387
- 邮箱:bochnerb@mskcc.org
学习地点
-
-
New Jersey
-
Basking Ridge、New Jersey、美国、07920
- 招聘中
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
Middletown、New Jersey、美国、07748
- 招聘中
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
Montvale、New Jersey、美国、07645
- 招聘中
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
-
New York
-
Commack、New York、美国、11725
- 招聘中
- Memorial Sloan Kettering Commack (Limited Protocol Activities)
-
接触:
- Bernard Bochner, PhD
- 电话号码:646-422-4387
-
East White Plains、New York、美国、10604
- 招聘中
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
接触:
- Eugene Pietzak, MD
- 电话号码:646-422-4781
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
首席研究员:
- Bernard Bochner, MD
-
Uniondale、New York、美国、11553
- 招聘中
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
接触:
- Bernard Bochner, MD
- 电话号码:646-422-4387
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Cohorts A and B Part 1
- High-grade (HG) NMIBC (HG Ta, CIS, and/or T1) of urothelial histology that is unresponsive to adequate BCG therapy.
- Stage, grade, and histology must be confirmed by the MSK Department of Pathology
- Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded
- In those subjects with CIS, the CIS must be present on the tumor sample from the most recent cystoscopy/TURBT
- In this context, adequate BCG therapy is defined as at least one of the following:
- At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy
- At least five of six doses of an initial induction course plus at least two of six doses of a second induction course
- Disease unresponsive to adequate BCG therapy is defined as the following. Suspected recurrence from suspicious cytology or cystoscopy, and later confirmed via TURBT, is acceptable:
- Persistent or recurrent CIS alone or with recurrent Ta/T1 disease (noninvasive papillary disease/tumor invades the subepithelial connective tissue) within 12 months of completion of adequate BCG therapy
- Recurrent HG Ta/T1 disease within 6 months of completion of adequate BCG therapy
- HG T1 disease at the first evaluation following an induction BCG course
Cohort C:
- Muslce invasive bladder cancer cT2-T4aN0-2 that has a predominant urothelial histology.
- Stage, grade, and histology must be confirmed by the MSK Department of Pathology
- Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded
Cohort A and B Only:
- In subjects with papillary tumors (Ta and T1), a complete TURBT must have been performed.
This is characterized by:
- Attainment of a visually complete resection of all papillary tumors (Ta and T1)
- Residual CIS not amenable to complete transurethral resection is acceptable
- Receipt of restaging transurethral resection for any tumor with invasion into the lamina propria (HG T1) as part of standard care, with documented presence of uninvolved detrusor muscle.
- Most recent cystoscopy/TURBT must have been performed within 6 months of the first dose of trial treatment.
- Absence of urothelial carcinoma involving the upper urinary tract (documented by radiological imaging or ureteroscopy).
- Have elected not to undergo or are considered ineligible for radical cystectomy, as determined by the treating surgeon. Reasons for ineligibility or refusal of radical cystectomy should be discussed with the subject as part of the informed consent process.
- Ineligibility factors for radical cystectomy may include, but are not limited to:
- Cardiovascular disease (e.g., recent acute coronary syndrome, arrhythmia, heart failure)
- Chronic obstructive pulmonary disease that would preclude a safe surgical procedure, as determined by the treating surgeon
- Poor performance status
- Prior major abdominal and pelvic surgery that would preclude a safe surgical procedure, as determined by the treating surgeon
Cohort C Only:
- Are willing to undergo a standard of care examination under anesthesia or cystoscopy within four weeks of scheduled radical cystetomy.
- Patients must have received 3-4 cycles of neoadjuvant Enfortumab Vedotin and pembrolizumab
- Age ≥18 years on day of signing informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2 / Karnofsky performance status ≥60%, as assessed within 28 days prior to treatment initiation.
- Required values for screening laboratory tests, performed within 28 days prior to treatment initiation:
Absolute neutrophil count (ANC) ≥1000/mm3
-
Platelets >75,000/mm3 without
-
Hemoglobin >8 g/dL
-
Creatinine clearance >40 mL/min for the dose-escalation phases, >25 mL/min for the dose expansion phases (estimated GFR can also be used in place of creatinine clearance)
-
AST/ALT ≤3 times the institutional upper limit of normal (ULN)
-
Total bilirubin ≤1.5 times the institutional ULN
-
Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.
-
Female subjects will be considered of non-reproductive potential if any of the following:
-
Postmenopausal [defined as at least 12 months with no menses without an alternative medical cause; in women <45 years of age a high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
-
Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening
-
Has a congenital or acquired condition that prevents childbearing
-
Male and female subjects of childbearing potential must agree, if participating in sexual activity that could lead to pregnancy, to use of an adequate method of contraception from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to 120 days after the last dose of trial therapy. Subjects should be informed that taking the study medication(s) may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study.
o Male subjects will be considered of non-reproductive potential if they have azoospermia (whether due to vasectomy or an underlying medical condition). Female subjects will be considered of non-reproductive potential if as described above. Acceptable methods of contraception:
-
Single method (one of the following is acceptable): intrauterine device, vasectomy of a female subject's male partner, or contraceptive rod implanted into the skin
-
Combination method (requires use of two of the following): diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide), cervical cap with spermicide (nulliparous women only), contraceptive sponge (nulliparous women only), male condom or female condom (cannot be used together), or hormonal contraceptive [oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection
-
Male subjects must agree not to donate sperm during and after the study
-
Able to comply with the treatment schedule as determined by the participant and the licensed practitioner.
-
Cohort B Part 2
-
Subjects with BCG-naïve High-grade Ta NMIBC are eligible. BCG-naïve NMIBC is defined as patients with no prior BCG exposure or no BCG treatment within 2 years of trial start.
- Stage, grade, and histology must be confirmed by the MSK Department of Pathology
- Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded
-
A complete TURBT must have been performed, as characterized by:
o Attainment of a visually complete resection of all tumors
-
Most recent cystoscopy/TURBT must have been performed within 60 days of the first dose of trial treatment
-
Absence of urothelial carcinoma involving the upper urinary tract (documented by radiological imaging or ureteroscopy)
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 / Karnofsky performance status ≥60%, as assessed within 28 days prior to treatment initiation
-
Required values for screening laboratory tests, performed within 28 days prior to treatment initiation:
- Absolute neutrophil count (ANC) ≥1000/mm3 independent of growth factor support
- Platelets >75,000/mm3 without receiving transfusion within 4 weeks prior to screening
- Hemoglobin >8 g/dL without receiving transfusion within 4 weeks prior to screening
- Creatinine clearance (measured or calculated per institutional standard) >40mL/min; estimated GFR can also be used in place of creatinine clearance
- AST/ALT ≤3 times the institutional upper limit of normal (ULN)
- Total bilirubin ≤1.5 times the institutional ULN (except for participants with Gilbert's Syndrome or of non-hepatic origin)
-
Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.
o Female subjects will be considered of non-reproductive potential if any of the following: oPostmenopausal [defined as at least 12 months with no menses without an alternative medical cause; in women <45 years of age a high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.] Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening
-
Has a congenital or acquired condition that prevents childbearing
-
Male and female subjects of childbearing potential must agree, if participating in sexual activity that could lead to pregnancy, to use of an adequate method of contraception from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to 120 days after the last dose of trial therapy. Subjects should be informed that taking the study medication(s) may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study.
- Male subjects will be considered of non-reproductive potential if they have azoospermia (whether due to vasectomy or an underlying medical condition). Female subjects will be considered of non-reproductive potential if as described above.
- Acceptable methods of contraception:
-
Single method (one of the following is acceptable): intrauterine device, vasectomy of a female subject's male partner, or contraceptive rod implanted into the skin
-
Combination method (requires use of two of the following): diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide), cervical cap with spermicide (nulliparous women only), contraceptive sponge (nulliparous women only), male condom or female condom (cannot be used together), or hormonal contraceptive [oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection]
-
Male subjects must agree not to donate sperm during and after the study
-
Willing and able to provide written informed consent/assent for the trial
-
Able to comply with the treatment schedule as determined by the participant and the licensed practitioner
Exclusion Criteria:
(Cohort A and B) Part 1
- History of or currently being treated for muscle-invasive (T2, T3, T4) locally-advanced non-resectable or metastatic urothelial carcinoma.
- Evidence of concurrent extravesical (i.e., urethra, ureter, or renal pelvis) urothelial cell carcinoma.
- Concurrent anti-cancer therapy, including investigational agents
Exceptions include:
-
Cohorts A and B Exceptions: Subjects on topical therapy (e.g. topical 5-
-
Cohort C Exceptions: Subjects on topical therapy (e.g. topical 5-fluorouracil) and Neoadjuvant chemotherapy (e.g. cisplatin and gemcitabine)
-
Has undergone any intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy/TURBT to starting trial treatment (a single dose of intravesical treatment given as part of the most recent cystoscopy/TURBT, during the screening period, such as with chemotherapy as per local/regional practices, is acceptable).
-
Have received any other neoadjuvant treatment other than Enfortumab Vedotin and pembrolizumab for muscle invasive bladder cancer
-
Has had prior chemotherapy, targeted small molecule therapy, cytokine therapy, or radiation therapy within 2 weeks prior to the first dose of trial treatment or who has not recovered (i.e., Grade ≤1 or at baseline) from AEs due to a previously administered agent.
°Subjects with Grade ≤2 neuropathy or Grade ≤2 alopecia are an exception to this criterion and may qualify for the study
-
Major surgery or a wound that has not fully healed within 4 weeks prior to the first dose of trial treatment.
Rash from treatment < or = grade 2 for at least 1 month prior to enrollment.
-
Patients who develop a dermatologic toxicity attributed to enfortumab vedotin and/or pembrolizumab that requires ongoing treatment with oral or systemic corticosteroids or immune-modulating biologic therapies are not eligible to receive intratumoral 2141-V11.
-
Patients receiving dupilumab must have received their last dose of dupilumab at least 6 weeks prior to administration of 2141-V11.
-
Patients receiving any other immune-modulating biologic therapies for management of dermatologic toxicities are not eligible. ° If subject has undergone major surgery greater than 4 weeks prior, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
- Refer to detail description for the rest of the Inclusion/Exclusion criteria
-
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:(Cohort A) anti-CD40 antibody 2141-V11
Intravesically or intratumorally) of an anti-CD40 agonist antibody (2141-V11) for the treatment of subjects with BCG-unresponsive NMIBC who are considered ineligible for or have elected not to undergo radical cystectomy. |
Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Cohort B Part 1 Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points. Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination no sooner than 22 days of the last cycle of neoadjuvant therapy with enfortumab vedotin and pembrolizumab and prior to and within 4 weeks of planned radical cystectomy. |
|
实验性的:(Cohort B) Part 1 2141-V11, a fixed dose of 10mg , Part 2 Gemcitabine
Intratumoral 2141-V11 will be administered at the fixed dose of 10 mg established in Cohort B Part 1. Patients enrolled in Cohort B Part 2 will be randomized 1:1 to one of two treatment arms: Arm 1 (intravesical gemcitabine 2000 mg in 100 mL plus intratumoral 2141-V11 10 mg) or Arm 2 (intravesical gemcitabine 2000 mg in 100 mL monotherapy). |
Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Cohort B Part 1 Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points. Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination no sooner than 22 days of the last cycle of neoadjuvant therapy with enfortumab vedotin and pembrolizumab and prior to and within 4 weeks of planned radical cystectomy. Cohort B Part 2 is a nonblinded, randomized prospective trial to determine whether the combination of gemcitabine with 2141-V11 is more efficacious than gemcitabine monotherapy in patients with BCG-naïve HG Ta NMIBC Cohort B Part 2 is a nonblinded, randomized prospective trial to determine whether the combination of gemcitabine with 2141-V11 is more efficacious than gemcitabine monotherapy in patients with BCG-naïve HG Ta NMIBC |
|
实验性的:(Cohort C) expansion cohort 10 mg of 2141-V11
For patients in Cohort C, 10 mg of 2141-V11 will be administered as an intratumoral injection during standard of care cystoscopy no sooner than day 22 of the last cycle of neoadjuvant enfortumab vedotin + pembrolizumab and prior to and within four weeks of planned radical cystectomy. |
Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Cohort B Part 1 Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points. Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination no sooner than 22 days of the last cycle of neoadjuvant therapy with enfortumab vedotin and pembrolizumab and prior to and within 4 weeks of planned radical cystectomy. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
recurrence-free survival (RFS) Cohort B Part 2
大体时间:2 years
|
2 years
|
|
|
MTD/RP2D (Cohort A)
大体时间:2 years
|
The MTD will be defined as the dose level at which the estimated DLT rate from the MCRM model is closest to the target acceptable rate of 20%. If an MTD is not found after the full dose escalation study has been completed, the next dose recommended by the MCRM algorithm will be considered the RP2D. A DLT will be defined as the occurrence of any clinically significant grade 3 or 4 AE (per CTCAE version 5.0) within the DLT evaluation period that is considered by the Principal Investigator or designee to be possibly, probably, or definitely related to 2141-V11. |
2 years
|
|
Reported number of adverse events from baseline (start of 2141-V11 administration) up until the last follow-up visit after 2141-V11 administration (Cohort B)
大体时间:1 year
|
AE severity should be graded using CTCAE version 5.0. |
1 year
|
|
Progression of disease
大体时间:2 years
|
in all subjects will be defined as development of metastatic disease or death following radical cystectomy |
2 years
|
合作者和调查者
调查人员
- 首席研究员:Bernard Bochner, MD、Memorial Sloan Kettering Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 21-314
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.